Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis

Lung

Volumn 188, Issue 2, 2010, Pages 115-123

  Jackson, Robert M ^a,b   Glassberg, Marilyn K ^a   Ramos, Carol F ^b   Bejarano, Pablo A ^c   Butrous, Ghazwan ^d   Orlando Gómez Marín, Orlando ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b Miami VAHS   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Exercise; Idiopathic pulmonary fibrosis; Pulmonary hypertension; Sildenafil; Vasodilator

Indexed keywords

PLACEBO; SILDENAFIL;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DYSPNEA; EXERCISE TOLERANCE; EXPERIMENTAL DESIGN; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; LUNG DIFFUSION CAPACITY; MALE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCORING SYSTEM; SIDE EFFECT; SYNCOPE; THORAX PAIN; TREATMENT OUTCOME; VISION; WALKING;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PIPERAZINES; PULMONARY DIFFUSING CAPACITY; PURINES; SULFONES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VITAL CAPACITY;

EID: 77949875047     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-009-9209-8     Document Type: Article

References (16)

1. Shorr A, Wainright J, Cors C, Lettieri C, Nathan S (2007) Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30:715-721
2. Patel N, Lederer D, Borczuk A, Kawut S (2007) Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 132:998-1006
3. Nathan S, Noble P, Tuder R (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 175:875-880
4. Galie N, Ghofrani H, Torbicki A, Barst RJ, Rubin L, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
5. Ghofrani H, Wiedemann R, Rose F, Schermuly R, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360:895-900
6. Collard H, Anstrom K, Schwarz M, Zisman D (2007) Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131:897-899
7. American Thoracic Society/European Respiratory Society (2002) International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277-304
8. Statement American Thoracic Society (2002) Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111-117
9. Eaton T, Young P, Milne D, Wells AU (2005) Six-minute walk, maximal exercise tests reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171:1150-1157
10. Redelmeier D, Bayoumi A, Goldstein R, Guyatt G (1997) Interpreting small differences in functional status: the six-minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 155:1278-1282
11. Matts J, McHugh R (1978) Analysis of accrual randomized clinical trials with balanced groups in strata. J Chronic Dis 31:725-740
12. Leuchte H, Neurohr C, Baumgarter R, Holzpfel M, Giehrl W, Vogeser M, Behr J (2004) Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 170:360-365
13. Lettieri C, Nathan S, Barnett S, Ahmad S, Shorr A (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746-752
14. Hemnes A, Zaiman A, Champion H (2008) PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol 294:L24-L33
15. Ghofrani H, Reichenberger F, Kohstall M, Kohstall M, Mrose E, Seeger T, Olschewski H, Seeger W, Grimminger F (2004) Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp. A randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 141:169-177
16. Arcasoy S, Christie J, Ferrari V, Sutton M, Zisman D, Blumen-thal N, Pochettino A, Kotloff R (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167:735-740